Kornitzer Capital Management Inc. KS Raises Stock Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Kornitzer Capital Management Inc. KS boosted its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 26.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 389,160 shares of the company’s stock after acquiring an additional 81,155 shares during the quarter. Kornitzer Capital Management Inc. KS owned 1.51% of Establishment Labs worth $10,075,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its position in Establishment Labs by 3,244.4% during the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company’s stock worth $41,000 after acquiring an additional 584 shares during the last quarter. Baker Avenue Asset Management LP bought a new stake in Establishment Labs during the 3rd quarter valued at $59,000. Global Retirement Partners LLC bought a new stake in Establishment Labs during the 3rd quarter valued at $60,000. Lazard Asset Management LLC boosted its position in Establishment Labs by 104.5% during the 1st quarter. Lazard Asset Management LLC now owns 963 shares of the company’s stock valued at $64,000 after buying an additional 492 shares during the period. Finally, Deutsche Bank AG purchased a new position in shares of Establishment Labs in the fourth quarter valued at about $66,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ESTA has been the topic of several research analyst reports. Citigroup upped their target price on Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their target price on shares of Establishment Labs from $46.00 to $53.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Stephens reiterated an “overweight” rating and issued a $47.00 price target on shares of Establishment Labs in a research note on Thursday, January 11th. Finally, Mizuho upped their price objective on shares of Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $55.00.

Establishment Labs Stock Performance

Shares of ESTA stock traded down $5.19 during trading hours on Friday, reaching $47.38. The company had a trading volume of 427,182 shares, compared to its average volume of 319,381. The firm has a market cap of $1.30 billion, a PE ratio of -15.59 and a beta of 1.24. The business has a fifty day moving average price of $47.12 and a 200-day moving average price of $36.32. Establishment Labs Holdings Inc. has a one year low of $16.96 and a one year high of $77.55. The company has a debt-to-equity ratio of 10.26, a quick ratio of 1.67 and a current ratio of 3.06.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.16. The firm had revenue of $31.60 million during the quarter, compared to analyst estimates of $31.44 million. Establishment Labs had a negative net margin of 47.53% and a negative return on equity of 357.81%. The business’s revenue for the quarter was down 27.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.55) EPS. Sell-side analysts predict that Establishment Labs Holdings Inc. will post -1.58 earnings per share for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.